The trajectory of companies tied to the drug's legacy presents a complex investment scenario . While the initial success generated substantial returns , generic copies have significantly eroded revenue. Investing in related pharmaceutical firms now requires a thorough assessment of proprietary rights , evolving patient changes, and the possibility